Medical Professional Publications

Pharmacy and Therapeutics Committee Updates

(From the September 2015 Issue of MedStat)

For more detailed information, contact Kimberly Novak at Kimberly.Novak@NationwideChildren.org.

The following actions were taken at the August 6 Pharmacy & Therapeutics Committee meeting.

The following Drug Samples were DENIED: Brimonidine 0.33% topical gel (Mirvaso®) for use in Dermatology Clinic.

The Dose Standardization Policy and Guidelines were APPROVED. This policy will be posted on the Pharmacy intranet website. Additional communication is forthcoming.

The Behavioral Health Crisis Box was APPROVED. Additional communication is forthcoming.

A Utilization Review for antipyrene/benzocaine-containing otic products (Auralgan®/Aurodex®) was presented. Antipyrene/benzocaine-containing products wereREMOVEDfrom the Formulary. Additional communication is forthcoming.

A Six-month Formulary Review for insulin glulisine (Apidra®) was presented. Insulin glulisine was APPROVED for maintenance on the Formulary.

A Six-month Formulary Review for antihemophilic factor [recombinant] (Kogenate FS®) was presented. Antihemophilic factor [recombinant] was APPROVED for maintenance on the Formulary.

A Six-month Formulary Review for coagulation factor IX [recombinant] Fc fusion protein (Alprolix®) extended half-life was presented. Coagulation factor IX [recombinant] Fc fusion protein (Alprolix®) extended half-life was APPROVED for maintenance on the Formulary.

A Six-month Formulary Review for antihemophilic factor VIII [recombinant] Fc fusion protein (Eloctate®) was presented. Antihemophilic factor VIII [recombinant] Fc fusion protein was APPROVED for maintenance on the Formulary.

The following Drug Cards were APPROVED: Carfilzomib (investigational agent).

myChildren’s mobile app

iPhone and Android.

Download Today! »

Nationwide Children's Hospital
700 Children's Drive Columbus, Ohio 43205 614.722.2000